Scots gene group in academic tieup with UCL

Synpromics, the Scottish life sciences company, today announces a collaboration with UCL Great Ormond Street Institute of Child Health, to develop gene therapies for pathologies affecting the haematopoietic system.

This new partnership further expands Synpromics’ activities in the cell and gene therapy sector, as it builds on its strategy of establishing partnerships with leading academics in the UK to integrate its technology into the next generation of gene-based medicines.

This research and development agreement with Professor Adrian Thrasher’s clinical research group at UCL Great Ormond Street Institute of Child Health, will develop synthetic tissue-specific promoters for use in the specialised cells of the immune system including lymphoid, myeloid and microglia cells.

Dr Michael Roberts, the founder and chief scientific officer (CSO) of Synpromics, said the company was “tremendously excited” at the prospects for the partnership.